An update on the surgical management of pterygium and the role of loteprednol etabonate ointment
John D Sheppard,1 Arnulfo Mansur,2 Timothy L Comstock,3 John A Hovanesian4 1Virginia Eye Consultants, Norfold, VA, USA; 2Airala's Laser and Cataract Institute, Miami, FL, USA; 3Bausch and Lomb, Inc., Rochester, NY, USA; 4Harvard Eye Associates, Laguna Hills, CA, USAAbstract: Pterygium, a su...
Guardado en:
Autores principales: | Sheppard JD, Mansur A, Comstock TL, Hovanesian JA |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f455995f31d3432bae0aae91bc53c118 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery
por: Timothy L Comstock, et al.
Publicado: (2011) -
Real world use of loteprednol etabonate ophthalmic gel 0.5% in cases representative of comorbid pathologies responding to minimally invasive glaucoma surgery
por: Sheppard JD, et al.
Publicado: (2019) -
Loteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trial
por: Fong R, et al.
Publicado: (2012) -
Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop
por: Coffey MJ, et al.
Publicado: (2013) -
Dose uniformity of loteprednol etabonate ophthalmic gel (0.5%) compared with branded and generic prednisolone acetate ophthalmic suspension (1%)
por: Marlowe ZT, et al.
Publicado: (2013)